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Abbreviations: 
 
AF:  Atrial fibrillation 
ASE:  American Society of Echocardiography 
BP:  Blood pressure 
BSA:  Body surface area 
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CFR:  Coronary flow reserve 
CHD:  Coronary heart disease 
CR:  Concentric remodeling 
CV:  Cardiovascular 
DD:  Diastolic dysfunction 
ECG:  Electrocardiographic 
HF:  Heart failure 
HTN:  Hypertension 
LAE:  Left atrial enlargement 
LAVI: Left atrial volume index 
LV:  Left ventricular 
LVEF:  Left ventricular ejection fraction 
LVH:  Left ventricular hypertrophy 
LVM:  Left ventricular mass 
LVMI:  Left ventricular mass index 
RWT:  Relative wall thickness 
SCD:  Sudden cardiac death 
VEA:  Ventricular ectopic activity 
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Abstract 
 
Abnormal left ventricular (LV) geometry, including LV hypertrophy (LVH), is associated with 
increased risk of major cardiovascular (CV) events and all-cause mortality and may be an 
independent predictor of morbid CV events.  Patients with LVH have increased risk of 
congestive heart failure, coronary heart disease, sudden cardiac death and stroke.  We review the 
risk factors for LVH and its consequences, as well as the risk imposed by concentric remodeling 
(CR).  We also examine evidence supporting the benefits of LVH regression, as well as evidence 
regarding the risk of CR progressing to LVH, as opposed to normalization of CR.  We also 
briefly review the association of abnormal LV geometry with left atrial enlargement and the 
combined effects of these structural cardiac abnormalities.   
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Abnormalities in left ventricular (LV) geometry , including LV hypertrophy (LVH) , are targeted 
responses to chronic arterial hypertension (HTN) and other cardiovascular (CV) disorders; and 
LVH is an independent risk factor for coronary heart disease (CHD), heart failure (HF), 
arrhythmias, including sudden cardiac death (SCD), stroke, and other major CV morbidity and 
mortality.
1
 According to Laplace's law, in the short-term, increases in LV mass (LVM) may be 
beneficial by allowing for a reduction in LV wall stress and hemodynamic compromise.  On the 
other hand, in the long-term, LV geometric abnormalities, particularly LVH, can deteriorate to 
maladaptive processes and increase the risk of HF and other CV disorders.
2
  Clearly, numerous 
epidemiological studies have demonstrated that LVH is not benign but is associated with very 
high prevalence of morbid CV events, and in most instances, LVH seems to be a more potent 
risk factor than other conventional CV risk factors for predicting major CV morbidity and 
mortality.
1,3-6
   
 
In this review, we discuss the various types of LV geometric abnormalities, including concentric 
remodeling (CR) and concentric and eccentric LVH (cLVH and eLVH, respectively).  We also 
review the risk factors for LVH, its consequences, and implications for regression.  Additionally, 
we review the more subtle LV geometric abnormality of CR and its predictive value for CV 
events, as well as implications for preventing the conversion of CR to frank LVH.  Finally, we 
discuss the impact of obesity on LV geometric abnormalities and the association of LV 
geometric abnormalities with other structural abnormalities, particularly left atrial enlargement 
(LAE).   
 
Risk Factors 
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The major risk factors for LVH are listed in Table 1.  Epidemiologic studies have identified age, 
elevated blood pressure (BP) and weight as independent risk factors for the development of 
LVH.
1,7
  Obviously, BP and weight typically increase with age, not surprisingly markedly 
increasing the prevalence of LVH in the elderly.  LVH is also related with other conditions 
including diabetes,
8
 hyercholesterolemia,
9
 myocardial infarction,
10
 valvular stenotic and 
regurgitant lesions,
11
 as well as African American race.
12 
 Additionally, high sodium intake, 
independent of level of BP, also increases the prevalence of LVH,
1,7
 as do other factors listed in 
Table 1.   
 
Consequences of LVH 
As discussed earlier, although initially LVH may be compensatory and benign, for decades it has 
been known to be associated with numerous adverse CV consequences (Table 2 and Figure 1).  
More than 3 decades ago, data from the Framingham Heart Study demonstrated that definite 
electrocardiographic (ECG) evidence of LVH, both by voltage and with repolarization 
abnormalities or "strain" pattern on the EGC, was associated with 6-fold and 8-fold increases in 
CHD and CV mortality, respectively.
10
 Clearly, as LVH as assessed by LVM index (LVMI) 
increases, so does the risk of major CV events. 
 
Coronary Flow Reserve (CFR)  The ability of the coronary arteries to increase their blood flow 
under stress is referred to as CFR, which is markedly reduced in patients with LVH due to HTN 
or aortic stenosis.
1,13
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LV Function  Certainly, LVH is associated with development of HF with either preserved or 
reduced levels of systolic function.
2
  Clearly, ECG-LVH with "strain" pattern predicts both new 
onset HF and increased mortality, with LVH predicting HF events more so than CHD events.
10
 
 
Although the exact mechanism by which LVH impacts LV function is not totally known, LVH 
and myocardial fibrosis may adversely affect diastolic dysfunction (DD).  Although LVM and 
relative wall thickness (RWT) may both increase DD in HTN, studies have also demonstrated 
that combined HTN and obesity (discussed below) have significant adverse impact on LV 
diastolic filling. 
1,7
  Although LVH is associated more strongly with DD than with systolic 
dysfunction,
1,7,13
 we recently demonstrated that 13% of patients with preserved LV systolic 
function but with cLVH progressed to LV systolic dysfunction during 3-year follow-up, 
indicating that LVH impacts diastolic and systolic HF.
2
   
 
Ventricular Ectopic Activity (VEA) Messerli and colleagues
2
 demonstrated three decades ago 
that ECG-LVH was associated with the high prevalence of premature and complex VEA, which 
may partly explain the known association of LVH, especially ECG-LVH, with increased risk of 
SCD.  Several echocardiographic studies have demonstrated increased risk of complex VEA and 
risk of SCD,
5,15
 whereas regression of LVH may be associated with reduced risk of SCD.
16
  
 
Additionally, LVH is a strong risk factor for atrial fibrillation (AF),
17,18
 including a 20% increase 
in the risk of AF for every one standard deviation increase in LVM.
17
  Also, ECG-LVH appears 
to be an independent risk factor for AF,
18
 whereas regression of ECG-LVH was associated with 
reduced risk of AF.
19
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Increased CV Events  Early studies from the Framingham Heart Study demonstrate marked 
increases in CHD events, HF, and SCD associated with ECG-LVH.
10
  During the last three 
decades, two studies from the Framingham Heart Study
3,20
 and elsewhere
4,6 
all clearly 
demonstrate marked increases in CV morbidity and mortality associated with echocardiographic 
LVH.
1,7
  Typically, studies have demonstrated a greater increase in CV risk across the spectrum 
of LVM and LVH.
1,21
  The risk associated with specific LV geometric profiles is discussed 
below.  
 
In addition to CV diseases, LVH also appears to be associated with and predictive of renal end-
points and other target organ damage.
1,22
 However, despite the very strong association of LVH 
with CV and non-CV risk, LVH is not often included as a standard CV disease risk factor. 
 
Specific Abnormalities in LV Geometry  
Typically, HTN and other CV disorders can include 4 distinct patterns of LV geometry based on 
the relationship between LV cavity size and RWT, including CR, as well as eLVH and cLVH 
(Figure 2).
23
  
 
The subtle LV geometric abnormality of CR is defined as an increase in RWT with normal 
LVMI, whereas increased LVMI indicates LVH, either cLVH if RWT is also increased or   
eLVH if RWT is normal.  Although the exact cut-points have varied (e.g. one classification 
defined RWT ≥ 0.45 as increased and LVMI > 125g/m2 as increased), the American Society of 
Echocardiography (ASE) currently defines increased LVMI as > 115 g/m
2
 for men and > 95 
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g/m
2
 in women and RWT, calculated as 2 x posterior wall thickness in diastole/LV internal 
diameter > 0.42.
24
   
 
Alterations in LV geometry other than LVH have not typically been appreciated as important CV 
risk factors.
1,25
  However, many studies have demonstrated that specific LV geometry and type 
of LVH may be an important factor in CV diseases, including HTN (Figure 3).
4
  In fact, Koren  
et al
4
 ,in a large study of patients with HTN, demonstrated an over 2-fold increase in CV events 
in those with CR compared with normal LV geometry, with CV events markedly and 
progressively increasing with eLVH and cLVH. 
 
Recently, we have assessed the prevalence of abnormal LV geometry in echocardiographic 
patients with normal left ventricular ejection fraction (LVEF), defined as  ≥ 50%, demonstrating 
that over one-third had CR, and over 10% had echocardiographic LVH, almost evenly divided 
between eLVH and cLVH.
25
 In a study of 35,602 patients with normal LVEF, Milani et al
25
 
demonstrated marked increases in mortality associated with CR, similar to that noted with 
eLVH, with a further marked increase in mortality with cLVH (Figure 4).  Since patients with 
reduced LVEF or advanced valvular heart disease were not included in this study, eLVH may not 
carry as high of a risk compared with some HF or valvular heart disease studies.  In a study by 
Lavie et al
26
 in patients > 70 years of age, CR was present in 43% of elderly, and in this elderly 
cohort, CR and cLVH were associated with marked increases in mortality compared with normal 
LV geometry and even more than those with eLVH.   
 
Impact of Obesity 
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As previously discussed, obesity is one of the strongest predictors for abnormal LV geometry, 
including LVH, and typically obesity increases with age and is a strong risk factor for HTN.
1,7,27
  
Clearly, we have recently demonstrated that abnormal LV geometry,  including both CR and 
both eLVH and cLVH, are more common in obese than leaner patients, with the same impact of 
obesity on abnormal LV geometry  noted in both women and men.
27,28
   
 
Additionally, we have identified a strong "obesity paradox" in many cohorts with CV diseases, 
as discussed in detail elsewhere.
29-32
  Despite the increased prevalence of abnormal LV geometry  
in obesity, which is typically associated with worse overall CV prognosis, we still demonstrated 
better survival among obese men and women compared to their leaner counterparts.
27,28
  In fact, 
for every LV geometric profile (normal LV geometry, CR, eLVH and cLVH), obese had lower 
mortality than did the leaner patients (Figure 5).
28
   
 
In our studies, we define LV geometry as recommended by the ASE and as used in many trials, 
and we indexed LVM to body surface area (BSA), using the LVMI method.
24
 However, many 
obesity researchers have suggested correcting LVM for some height or other allometric 
correction (e.g. height 
2.7
, using a cut-off of 50 g/m
2.7
 to define LVH) that may correlate better 
with lean body mass and reduce the variability in cohorts of normal subjects.
1,33
  Nevertheless, in 
our laboratory, correcting LVM for either BSA or height had similar prognostic power in obese 
and lean patients, and the BSA method predicted mortality slightly better than did the height 
method.
27,28
   
 
LV Geometry and Left Atrial Enlargement  
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It is well known that there is a close relationship between left atrial enlargement (LAE) and DD. 
Although numerous methods to assess DD by echocardiography are available, including pulsed-
Doppler of mitral inflow and mitral annular tissue Doppler imaging ,
 35 
which are beyond the 
context of this manuscript, a common result of many LV structural and functional abnormalities, 
including DD, is LAE
. 35-37
.Likewise, studies indicate that LVH is an independent predictor of 
LA size.
35
 In a study of 47,865 patients with LVEF ≥50%, we determined that both RWT and 
LVMI were independent predictors of LAE.  Although CR was associated with slight, but 
significant, increase in the prevalence of LAE, both eLVH and cLVH, were associated with two-
fold increases in the prevalence of LAE.  Furthermore, LAE was independently associated with 
abnormalities in LV geometry.
35 
Prior studies have indicated that LAE as assessed by left atrial 
volume index ( LAVI ) was a powerful predictor of survival in patients with CV diseases.
 36 
In a 
similar way, the combination of abnormal LV geometry and LAE in our study was associated 
with additive  effects on increasing all-cause mortality.
37
 Mild, moderate and severe LAE by 
LAVI were associated with 10%, 46% and 2.5-fold increased risk of mortality, respectively.
37
  In 
patients with normal LV geometry or CR, severe LAE was associated with increased mortality 
by 28% and 46%, respectively.  However, in eLVH and cLVH, the mortality risk with severe 
LAE was twice that of patients with a normal LAVI.
37
 
 
Regression of  Abnormal LV Geometry 
It is well known from both animal and human studies that anti-HTN therapies may cause 
regression of LVH and could be associated with reductions in CV morbidity and mortality.
1,38-44
  
Additionally, reversing LVH has been shown to improve systolic and diastolic function, improve 
abnormal CFR, and reduce overall CV risks. 
1,3,40,41
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Another noteworthy finding from our data was that subjects with CR who reverted to a normal 
LV geometric pattern over time had improved survival, whereas those who converted from CR 
to LVH had marked increases in mortality (Figure 6).
25
 These data suggest that changes in CR 
over time may impact prognosis, similar to the many studies suggesting improvements in 
prognosis with regression of LVH.
1,25
  Therefore, improvements in LV geometry , including both 
CR and LVH, may be associated with overall benefits on CV prognosis and all-cause survival.   
 
Conclusions   
 
The constellation of findings suggests that abnormalities in LV geometry, including LVH, and, 
particularly, the more subtle finding of CR, are extremely common in patients referred for 
echocardiography, even those with preserved LVEF.  These abnormalities in LV geometry 
frequently coexist with other structural abnormalities, including LAE; and both abnormal LV 
geometry  and LAE are associated with significant increases in mortality risk.  We believe that 
routine echocardiographic reports should include data on LV geometry, including CR as well as 
LVH (both eLVH and cLVH).  Studies are needed to determine strategies to reduce 
abnormalities in LV geometry, which may be associated with improved prognosis in CV 
diseases.   
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Table 1.  Risk Factors for LVH 
 
Major 
 Age 
 Arterial pressure (including ambulatory, work, and exercise) 
 Weight 
Other 
 Race (Higher in African Americans) 
 Renin-angiotensin-aldosterone system 
 Increased sodium intake 
 Diabetes 
 Aortic stenosis and regurgitant valvular heart disease 
 Catecholamines 
 Job strain,including physical and emotional 
 Various growth factors  
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Table 2.  Consequences of LVH 
 
 
 Reduced coronary flow reserve 
 Reduced ventricular functional systolic reserve 
 Diastolic ventricular dysfunction  
 Increased coronary artery disease 
 Frequent and complex ventricular arrhythmias  
 Increased cardiovascular events 
 Increased cardiovascular mortality 
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Figure Legends 
 
1. Risk factors and consequences of LVH. 
2. Hemodynamic and geometric profiles in hypertensive patients with the 4 patterns of LV 
geometry. The short axis/long axis ratio (b/a) was described by 2-dimensional 
echocardiography. CI, cardiac index (l/min/m2); SBP, systolic blood pressure; TPR, total 
peripheral resistance (dynes s cm−5). Reproduced with permission from Ganau A et al.23 
3. Relation of LV geometry to mortality in patients with uncomplicated hypertension. CH, 
concentric hypertrophy; EH, eccentric hypertrophy; NL, normal. Relative wall thickness 
is the ratio of the posterior wall thickness to one-half the left ventricular internal 
dimension at end-diastole. Reproduced with permission from Koren MJ et al.
4
 
4. Actuarial cumulative hazard plot for survival time based on cardiac structure. A, Normal 
structure, CR, and frank LVH. B, Normal structure, CR, eccentric hypertrophy (EH), and 
concentric hypertrophy (CH). Reproduced with permission from Milani RV et al.
25
 
5. Patients with CR who progress to LVH versus subjects who convert to normal (NL) 
cardiac structure. A, Kaplan-Meier survival over 3 years. B, RRs and 95% CIs of all-
cause mortality. Reproduced with permission from Milani RV et al.
25
 
6. Mortality prevalence in four LV geometric patterns by obesity status in female patients 
with normal ejection fraction.  Reproduced with permission from Patel DA et al.
28
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